ATE306272T1 - Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion - Google Patents

Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion

Info

Publication number
ATE306272T1
ATE306272T1 AT01964471T AT01964471T ATE306272T1 AT E306272 T1 ATE306272 T1 AT E306272T1 AT 01964471 T AT01964471 T AT 01964471T AT 01964471 T AT01964471 T AT 01964471T AT E306272 T1 ATE306272 T1 AT E306272T1
Authority
AT
Austria
Prior art keywords
receptor antagonist
aldosterone receptor
cognitive function
improve cognitive
aldosterone
Prior art date
Application number
AT01964471T
Other languages
English (en)
Inventor
Kenton N Fedde
Alfonzo T Perez
Joseph F Tooley
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE306272T1 publication Critical patent/ATE306272T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT01964471T 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion ATE306272T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22873800P 2000-08-28 2000-08-28
PCT/US2001/026760 WO2002017895A2 (en) 2000-08-28 2001-08-28 Use of an aldosterone receptor antagonist to improve cognitive function

Publications (1)

Publication Number Publication Date
ATE306272T1 true ATE306272T1 (de) 2005-10-15

Family

ID=22858397

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01964471T ATE306272T1 (de) 2000-08-28 2001-08-28 Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion

Country Status (10)

Country Link
US (2) US20020111337A1 (de)
EP (1) EP1313485B1 (de)
JP (1) JP2004507495A (de)
AT (1) ATE306272T1 (de)
AU (1) AU2001285318A1 (de)
CA (1) CA2419256A1 (de)
DE (1) DE60114027T2 (de)
DK (1) DK1313485T3 (de)
ES (1) ES2251505T3 (de)
WO (1) WO2002017895A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003043640A2 (en) * 2001-11-23 2003-05-30 Akzo Nobel N.V. Treatment of major depressive disorder using glucocorticoid receptor antagonists
KR20040104632A (ko) * 2002-04-26 2004-12-10 쉐링 악티엔게젤샤프트 호르몬 대체 요법을 받는 여성에서 고혈압의 치료
TW200400816A (en) 2002-06-26 2004-01-16 Lilly Co Eli Tricyclic steroid hormone nuclear receptor modulators
WO2004041288A1 (en) * 2002-11-05 2004-05-21 Schering Aktiengesellschaft Hormone replacement therapy with drospirenone
US7786101B2 (en) 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60330888D1 (de) * 2002-11-05 2010-02-25 Bayer Schering Pharma Ag Verwendung von drospirenon zur behandlung von hypertension
US20060167026A1 (en) * 2003-01-06 2006-07-27 Hiroyuki Nawa Antipsychotic molecular-targeting epithelial growth factor receptor
US7485094B2 (en) * 2003-09-30 2009-02-03 Smithmarks, Inc. Methods of diagnosis using pulse volume measurement
EP2051696A2 (de) * 2006-08-18 2009-04-29 Morton Grove Pharmaceuticals, Inc. Stabile flüssige levetiracetam-zusammensetzungen und verfahren
US20090265215A1 (en) * 2008-04-22 2009-10-22 Paul Bernhard Lindstrom Methods and apparatus to monitor audience exposure to media using duration-based data
WO2012059594A1 (en) * 2010-11-04 2012-05-10 Bayer Pharma Aktiengesellschaft Mineralcorticoid receptor antagonists for the treatment of corticoid-induced obesity
RU2598842C2 (ru) 2011-01-20 2016-09-27 Мерк Шарп Энд Домэ Корп. Антагонисты рецептора минералокортикоидов
EP2697203B1 (de) 2011-04-13 2017-05-24 Merck Sharp & Dohme Corporation Mineralkortikoid-rezeptorantagonisten
ES2592818T3 (es) 2011-10-13 2016-12-01 Merck Sharp & Dohme Corp. Antagonistas del receptor de mineralocorticoides
EP2765859B1 (de) 2011-10-13 2017-01-18 Merck Sharp & Dohme Corp. Mineralkortikoid-rezeptorantagonisten
ES2592518T3 (es) 2011-10-13 2016-11-30 Merck Sharp & Dohme Corp. Antagonistas del receptor de mineralocorticoides
AR091731A1 (es) 2012-07-19 2015-02-25 Merck Sharp & Dohme Antagonistas del receptor de mineralocorticoides
WO2017083795A1 (en) * 2015-11-13 2017-05-18 Pietro Paolo Sanna Methods and compositions for treating alcohol use disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3133012A (en) * 1961-06-28 1964-05-12 Universal Oil Prod Co Combination catalytic reforming process
US3257390A (en) * 1963-06-12 1966-06-21 Merck & Co Inc Ring a unsaturated 21-hydroxy-3-oxo-17alpha-pregnane-17-carboxylic acid lactone diuretic agents
IE51145B1 (en) * 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
FI77669C (fi) * 1983-04-13 1989-04-10 Ciba Geigy Ag 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat.
DE3506100A1 (de) * 1985-02-18 1986-08-21 Schering AG, 1000 Berlin und 4709 Bergkamen 1(alpha).7(alpha)-dithiosubstituierte spirolactone, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
AU642066B2 (en) * 1991-01-25 1993-10-07 Nanosystems L.L.C. X-ray contrast compositions useful in medical imaging
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5529992A (en) * 1992-04-21 1996-06-25 Curators Of The University Of Missouri Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
PT944644E (pt) * 1996-12-11 2003-02-28 Searle & Co Processos para a preparacao de esteroides 9,11-epoxi e intermediarios uteis para esse efeito
DE19654609A1 (de) * 1996-12-20 1998-06-25 Schering Ag Therapeutische Gestagene zur Behandlung von Premenstrual Dysphoric Disorder
HK1040056A1 (zh) * 1998-11-06 2002-05-24 G.D. Searle & Co. 血管紧张肽转换酶抑制剂及醛甾䣳对抗物的综合治疗以减低心血管疾病的发病率及死亡率
UA74141C2 (uk) * 1998-12-09 2005-11-15 Дж.Д. Сірл Енд Ко. Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти)
IL145237A0 (en) * 1999-03-05 2002-06-30 Searle & Co Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
DE60114027T2 (de) 2006-07-13
EP1313485B1 (de) 2005-10-12
DE60114027D1 (de) 2006-02-23
JP2004507495A (ja) 2004-03-11
WO2002017895A2 (en) 2002-03-07
CA2419256A1 (en) 2002-03-07
WO2002017895A3 (en) 2003-02-06
US20060058274A1 (en) 2006-03-16
ES2251505T3 (es) 2006-05-01
DK1313485T3 (da) 2005-12-27
EP1313485A2 (de) 2003-05-28
AU2001285318A1 (en) 2002-03-13
US20020111337A1 (en) 2002-08-15

Similar Documents

Publication Publication Date Title
ATE306272T1 (de) Verwendung von einem aldosteron-rezeptor- antagonisten zur verbesserung der kognitiven funktion
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE311200T1 (de) Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten
AUPO755097A0 (en) Receptor agonist and antagonist
ATE401909T1 (de) Verwendung von löslichen ctla4-mutanten zur behandlung von rheumatoider arthritis
PT1349839E (pt) Derivados de feniletenilo ou feniletinilo como antagonistas do receptor de glutamato
ATE494904T1 (de) Verbindungen und verfahren zur erhöhung der neurogenese
DE60140377D1 (de) Mch antagonisten und deren verwendung zur behandlung von fettleibigkeit
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
MXPA04008772A (es) Composiciones de clorhidrato de naltrexona.
DE60043308D1 (de) Verfahren zur behandlung der schädigung des zentralnervensystems durch ischämie oder durch hämorrhagie mit antagonisten von alpha4 integrin
EA200400029A1 (ru) КОМБИНАЦИЯ АНТАГОНИСТА РЕЦЕПТОРА АЛЬДОСТЕРОНА И ИНГИБИТОРА ГМГ-КоА-РЕДУКТАЗЫ
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
EP1282432A4 (de) METHODE ZUR VERWENDUNG VON PEPTIDANTAGONISTEN VON ZONULIN ZUR PRäVENTION BZW. VERZöGERUNG DER ENTSTEHUNG VON DIABETES
BR0313534A (pt) Antagonistas de integrinade ácido carboxìlico de piperidinoìla
ATE371454T1 (de) Antagonisten der prostaglandin ep2 und/oder ep4 rezeptoren zur behandlung von menorrhagie
DZ3361A1 (fr) Cyclohéxylamines bicycliques et leur utilisation comme antagonistes des récepteurs de nmda
ATE381938T1 (de) Verwendungen zur behandlung von fsh-verbundenen zuständen mit gnrh antagonisten
ATE385789T1 (de) Verwendung von einem aldosteronantagonist zur behandlung und vorbeugung von aldosteron- vermittelten pathogenen zuständen
IL162475A0 (en) Method of treating ophthalmic disorders with epoxy-steroidal aldosterone receptor antagonists
ATE367160T1 (de) Piperazin-derivate zur verwendung als ccr-3 rezeptor antagonisten zur behandlung von asthma
ATE310537T1 (de) Kombinationstherapie von angiotensin- konvertierendem enzymhemmer und epoxy-steroidalem aldosteron antagonist zur behandlung von kardiovaskulären erkrankungen
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
EA200401137A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
ATE333869T1 (de) Verwendung von mglur5 antagonisten zur behandlung von pruritischen zuständen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1313485

Country of ref document: EP

REN Ceased due to non-payment of the annual fee